Skip to content
TickerMagic

Torrent Pharmaceuticals Limited

TORNTPHARMNSEHealthcare
₹4,611
+0.30 (+0.01%) · EOD 2026-11-20

Our verdict

Sell

Quality (51/100) does the heavy lifting; valuation (4/100) is the drag.

ExpensiveHealth BOvervalued
Quality 51Momentum 46Value 4Trend 43The Spark ↓

Our fair value

Overvalued by 50%
₹2,305.5down 50.00%
Price ₹4,611Range ₹2,121 – ₹2,983

Buy-below (20% margin of safety): ₹1,844.4

The bottom line

Our blended model reads Torrent Pharmaceuticals Limited as a Sell at 34/100. At ₹4,611 it trades above our blended DCF and relative-multiples fair value of ₹2,305.5, about 50% downside to that estimate — we read it as overvalued by 50%. On 70.3x trailing earnings it sits pricier than the Healthcare median of about 37.4x. The price is about 10% below its 52-week high of ₹5,122.8 and 26% above the low of ₹3,654.13. Financial health scores 72/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹4,878.79 implies about 6% upside across 28 analysts. It clears 6 of 13 investability checks, with durability 51, valuation 7 and momentum 46 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹2,305.5down 50.00%
Overvalued by 50%
Price ₹4,611Range ₹2,121.06–₹2,983.21
DCF + relative blendmedium confidence

With a 20% margin of safety, our buy-below price is ₹1,844.4.

Analyst views

28 analysts22 buy · 5 hold · 1 sell
12-month consensus target₹4,878.79up 5.81%

1-year price

EOD · 2026-11-20
1D
up 0.01%
1W
down 2.46%
1M
up 1.15%
3M
down 7.24%
6M
up 3.59%
1Y
—

52-week range

-9.99% from the 52-week high.

Trend check
Below 50-DMA₹4,739Above 200-DMA₹4,551

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell34
B
Financial health 72/100
Altman Z 3.89 · Safe zone

Piotroski F-score 3/9 — quality of earnings & balance sheet.

Our scores

Durability51
Valuation7
Momentum46

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 6 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 17.0%
  • Fail: Low debt (D/E < 0.5): 0.85x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 42%
  • Fail: Earnings growing: -22%
  • Pass: Net margin ≥ 10%: 15.5%
  • Fail: Current ratio > 1.5: 1.13
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 3.89
  • Fail: Piotroski ≥ 7: 3/9

Quarterly results

Revenue · 1Q2026
₹4,197 Cr
Net profit
₹434 Cr
Margin
10%
2Q2025
3Q2025
4Q2025
1Q2026
Revenue Net profitLatest revenue QoQ +27%

Annual financials

Revenue · 2026
₹13,980 Cr
Net profit
₹2,229 Cr
Margin
16%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +21%

Shareholding

  • Promoter71.2%
  • Institutions15.9%
  • Public & other12.9%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹1.52 L Cr
P/E ratio
70.3
P/B ratio
18.06
EPS (TTM)
₹64.1
ROE
17.0%
Debt / Equity
0.85x
Profit margin
15.5%
Free cash flow
₹2,601 Cr
52-week high
₹5,122.8
-9.99% from high
52-week low
₹3,654.13
Dividend yield
0.8%
Beta
0.14
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Healthy profit margin (15.5%).
  • Financially solid — Altman Z 3.89.

Opportunities

  • Revenue growing (42% YoY).

Bear case

Weaknesses

  • Weak Piotroski score (3/9).

Threats

  • Earnings contracting year on year.
  • Rich valuation versus sector peers.
  • Trades ~50% above our estimated fair value.

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Limited researches, develops, manufactures, and distributes branded and generic pharmaceutical formulations across India, the United States, Brazil, Germany, Malta, and other markets. The company offers products spanning multiple therapeutic categories including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, and pulmonology treatments.

Torrent Pharmaceuticals Limited — frequently asked questions

Is Torrent Pharmaceuticals Limited a buy, hold or sell?

TickerMagic currently rates Torrent Pharmaceuticals Limited (TORNTPHARM) a Sell, based on a blended score of 34/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Torrent Pharmaceuticals Limited's fair value?

Our blended DCF and relative-valuation model estimates Torrent Pharmaceuticals Limited's fair value at about ₹2,305.5, versus a current price of ₹4,611 — roughly 50% downside. On that basis the stock looks overvalued by 50%.

Is Torrent Pharmaceuticals Limited financially healthy?

Torrent Pharmaceuticals Limited scores 72/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.

How has Torrent Pharmaceuticals Limited's share price performed?

Torrent Pharmaceuticals Limited is down 7% over three months, and last traded at ₹4,611. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.